Get the Stockscreener App
15.91
1.73%
-0.28
Pre-market:
15.53
-0.38
-2.39%
Tyra Biosciences Inc stock is traded at $15.91, with a volume of 186.50K.
It is down -1.73% in the last 24 hours and up +13.64% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
See More
Previous Close:
$16.19
Open:
$16.32
24h Volume:
186.50K
Relative Volume:
0.53
Market Cap:
$805.09M
Revenue:
-
Net Income/Loss:
$-69.13M
P/E Ratio:
-9.882
EPS:
-1.61
Net Cash Flow:
$-50.91M
1W Performance:
-0.19%
1M Performance:
+13.64%
6M Performance:
-19.36%
1Y Performance:
+21.17%
1-Day Range:
$15.72
$16.58
1-Week Range:
$15.72
$17.27
52-Week Range:
$12.34
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
15.91 | 805.09M | 0 | -69.13M | -50.91M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Tyra Biosciences director Nina Kjellson sells shares worth $409,645 By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells shares worth $409,645 - MSN
Trading (TYRA) With Integrated Risk Controls - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.1%Time to Sell? - MarketBeat
Barclays PLC Has $884,000 Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences (NASDAQ:TYRA) Trading 7.9% HigherHere's What Happened - MarketBeat
JPMorgan Chase & Co. Has $8.67 Million Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences (NASDAQ:TYRA) Given Buy Rating at HC Wainwright - Defense World
Tyra Biosciences' (TYRA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC - Urology Times
Tyra Falls on FDA Nod - Baystreet.ca
Tyra Biosciences advances bladder cancer drug trial - Investing.com
Tyra Biosciences advances bladder cancer drug trial By Investing.com - Investing.com South Africa
Tyra Biosciences Secures FDA Clearance for TYRA-300 Phase 2 Bladder Cancer Trial - StockTitan
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $31.00 Average Target Price from Brokerages - Defense World
UBS Group Initiates Coverage on Tyra Biosciences (NASDAQ:TYRA) - Defense World
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Coverage Initiated at UBS Group - MarketBeat
UBS backs Tyra Biosciences stock with long-term growth forecast driven by TYRA-300 pipeline - Investing.com Canada
12,647 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Bought by Franklin Resources Inc. - Defense World
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stake Lifted by Barclays PLC - Defense World
Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest - MarketBeat
(TYRA) Trading Report - Stock Traders Daily
State Street Corp Acquires 16,248 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.3%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Wellington Management Group LLP Sells 26,207 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
The Take On Tyra Biosciences (NASDAQ:TYRA) - Seeking Alpha
(TYRA) Trading Signals - Stock Traders Daily
Tyra Biosciences to Present at Upcoming Investor Conferences - The Eastern Progress Online
The Manufacturers Life Insurance Company Invests $333,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate - Simply Wall St
Frazier Life Sciences Management L.P. Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Victoria Advocate
Janus Henderson Group PLC Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) - The Eastern Progress Online
(TYRA) Investment Analysis - Stock Traders Daily
Polar Asset Management Partners Inc. Buys New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Participate in 2023 Jefferies London Healthc - GuruFocus.com
Head to Head Survey: Tyra Biosciences (NASDAQ:TYRA) & Wellness Center USA (OTCMKTS:WCUI) - Defense World
Walleye Capital LLC Has $2.98 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Sio Capital Management LLC Has $9.42 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):